TVB-2640 (54) is a selective, potent, reversible FASN inhibitor (IC50 = 52 nM) evaluated for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) correlated with elevated hepatic de novo lipogenesis [193]. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.